Inactive Instrument

AB-BIOTICS SA Stock BME

Biotechnology & Medical Research

AB-Biotics SA, also known as AB Biotics, is a Spain-based company engaged in the biotechnology industry business sector. It is dedicated to the research and development (R&D) of functional ingredients, drugs and tools for genetic analysis, as well as the nutraceutical and pharmaceutical industries. The Companyâ€™s pipeline includes a range of supplements designed to improve health, from products that can lower the risk of cardiovascular disease to those that can help in the management of diabetes. It covers the development spectrum from marketed product, to proof-of-concept, and includes products that have been licensed to global food and pharmaceutical companies. The Company also provides outsourced R&D solutions to pharmaceutical companies, as well as functional food industry related companies. The Company offers different products, such as AB-Life, LipiGO, AB-Dentalac and AB-Colic, among others.

Employees

Sector

Biotechnology & Medical Research

More about the company

As early as today, start finding the best investment opportunities!

Market Cap	62.54M 54.98M 51.18M 47M 88.26M 6B 89.43M 608M 238M 2.96B 235M 230M 10.24B	P/E 2017	-21.2x	P/E 2018	31.7x
Enterprise Value	60.11M 52.84M 49.19M 45.17M 84.82M 5.76B 85.94M 585M 228M 2.85B 226M 221M 9.84B	EV / Sales 2017	2.22x	EV / Sales 2018	2.88x
Free-Float	31.56%	Yield 2017 *	-	Yield 2018	-

01/06/22	AB-Biotics, S.A. acquired Alifarm S.A. for EUR 3.5 million.	CI
07/11/19	Kaneka Europe Holding Company N.V. completed the acquisition of 18.21% stake in AB-Biotics, S.A.	CI
03/09/19	Kaneka Europe Holding Company N.V. made an offer to acquire remaining 33.67% stake in AB-Biotics, S.A. for €21.2 million.	CI
16/08/19	Kaneka Corporation has completed the voluntary offer to acquire an additional 26.57% stake in AB-Biotics, S.A. for €16.7 million.	CI
10/07/19	Kaneka Corporation made a voluntary public offer to acquire the remaining 60.24% stake in AB-Biotics, S.A. for €37.9 million.	CI
22/03/19	Ab-Biotics Sa Reports Earnings Results for the Full Year Ended December 31, 2018	CI
11/05/18	Kaneka Corporation Concludes License Agreement with AB-Biotics for Production and Sales of its Probiotics Products	CI
05/04/18	Kaneka Corporation completed the acquisition of 26.87% stake in AB-Biotics, S.A. from Corporacion Ivamosa, Gestion Y Administracion Mobiliaria, S.A., Capital MAB, FCR fund of Institut Català de Finances Capital, SGEIC, S.A. and Buanaventura Guamis.	CI
03/04/18	Kaneka Americas Holding Inc. enters into Licensing Agreement with AB-Biotics, S.A	CI
28/03/18	Kaneka Corporation signed an agreement to acquire 26.87% stake in AB-Biotics, S.A. from Corporacion Ivamosa, Gestion Y Administracion Mobiliaria, S.A., Capital MAB, FCR fund of Institut Català de Finances Capital, SGEIC, S.A. and Buanaventura Guamis.	CI
16/03/18	Corporacion Ivamosa and Gestion Y Administracion Mobiliaria, S.A. acquired 10% stake in AB-Biotics, S.A..	CI
08/11/17	Frutarom Industries Ltd. acquired AB-Fortis from AB-Biotics, S.A..	CI
25/10/16	AB-Biotics SA announced a financing transaction	CI

Director	Title	Age	Since
Sergi Audivert Brugué CHM	Chairman	-	-
Miquel Àngel Bonachera Sierra BRD	Director/Board Member	-	23/04/2004
Kazuhiko Fujii BRD	Director/Board Member	65	02/07/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB-BIOTICS SA	-.--%	-.--%	-	-	69.57M
VERACYTE, INC.	-1.77%	-2.88%	+120.24%	+104.15%	4.44B
ADAPTIVE BIOTECHNOLOGIES CORPORATION	+1.21%	+3.11%	+109.67%	+188.24%	3.61B
IOVANCE BIOTHERAPEUTICS, INC.	-1.80%	-2.39%	+56.55%	-30.30%	2.19B
BGI GENOMICS CO., LTD.	+3.12%	+3.21%	-28.32%	-36.33%	2.13B
CAREDX, INC.	-2.10%	-5.24%	+184.28%	+239.50%	1.88B
MARAVAI LIFESCIENCES HOLDINGS, INC.	-1.04%	-4.29%	+148.70%	-41.47%	987M
SEEGENE, INC.	+2.92%	+6.02%	-6.47%	+23.96%	875M
HANGZHOU ALLTEST BIOTECH CO., LTD.	+2.41%	-2.94%	-41.15%	-15.48%	491M
CURIOX BIOSYSTEMS CO., LTD	+2.96%	+12.06%	+2.70%	-	468M
Average	+0.59%	+1.01%	+60.69%	+54.03%	1.9B
Weighted average by Cap.	-0.04%	-0.33%	+85.60%	+85.54%

	2017	2018
Net sales	7.72M 6.79M 6.32M 5.8M 10.89M 740M 11.04M 75.09M 29.33M 366M 28.98M 28.35M 1.26B	12.59M 11.07M 10.31M 9.46M 17.77M 1.21B 18.01M 122M 47.84M 596M 47.28M 46.26M 2.06B
Net income	-895K -787K -732K -672K -1.26M -85.81M -1.28M -8.7M -3.4M -42.37M -3.36M -3.29M -146M	1.22M 1.07M 997K 916K 1.72M 117M 1.74M 11.85M 4.63M 57.69M 4.57M 4.47M 199M
Net Debt	-1.86M -1.63M -1.52M -1.4M -2.62M -178M -2.66M -18.07M -7.06M -87.97M -6.97M -6.82M -304M	-2.44M -2.14M -2M -1.83M -3.44M -234M -3.49M -23.72M -9.26M -115M -9.15M -8.96M -399M

AB-BIOTICS SA Stock BME

Stocks

Biotechnology & Medical Research

Valuation: AB-BIOTICS SA

Latest news : AB-BIOTICS SA

Managers and Directors: AB-BIOTICS SA

Bio Diagnostics & Testing

Financials

Company Profile